You are here

Imatinib (IM) versus hydroxychloroquine (HCQ) and IM for CML patients in CyR with detectable residual disease

Dear All,

I would like to thank Anjana for sharing the following update about another drug combination that targets the stem cell - shown success in the lab- that might lead to a possible cure.

The study is in the UK at:

The Paul O’Gorman Leukaemia Research Centre 

Gartnavel General Hospital,

Glasgow, UK

Lead investigator is Prof.Tessa Holyoake who has been researching the role of quiescent stem cells in residual disease for some years now.

 

The study has 2 arms- one control and one interventional ... as described  below:

Imatinib alone arm: Patients will continue to receive the once-daily dose of imatinib (oral) that they were receiving prior to entry in the trial. This is the control arm of the study. 

Imatinib + HCQ arm: Patients will continue to receive the once-daily dose of imatinib (oral) that they were receiving prior to entry in the trial. In addition they will receive HCQ (oral), 400 mg twice-daily. This is the interventional treatment under study. 
Total duration of interventions: 12 months  

http://www.controlled-trials.com/isrctn/pf/61568166

 

Best wishes,

Sandy

 

 

 

I have just heard from Prof. Holyoake that the above study.....' is open in Glasgow and Liverpool and just waiting approvals to open in Hammersmith. 5 patients have been recruited with another 4 in screening'

 

Given the prestige of the clinicians/investigators involved, this study might turn out to be a breakthrough- at least in understanding how/why CML stem cells are resistant to TKI therapy. Hopefully the pay-off for the patients who enrol in this study will be a 'cure'- wouldn't that be great!

 

Best wishes,

Sandy